Fuertes Abardia C, Ballesta Juan P, Cruz Esteve I, Galindo Ortego G, Marsal Mora JR, Gomez-Arbones X. Potentially inappropriate prescribing: usefulness of STOPP/START criteria version 2 in Catalonian elderly population. Semergen. 2022 Apr;48(3):163-73. doi: 10.1016/j.semerg.2021.09.005
Montserrat-Capdevila J, Godoy P, Marsal JR, Ortega M, Pifarre J, Barbe F. Comorbidity in mental health in patients diagnosed with chronic obstructive pulmonary disease. Semergen. 2020 Jan;46(1):53-9. doi: 10.1016/j.semerg.2019.08.002
Wolowacz SE, Petrillo J, Doward LC, Briggs A. Measuring health-state utility values in clinical trials: can we do better? Ispor Connections. 2014 Sep;20(5):4-8.
Stull DE, Houghton KF, Petrillo J. Innovative data analysis for demonstrating product value: analysis of heterogeneity in treatment response in clinical trials. Ispor Connections. 2013;19(1):5-8.
Masters E, Zlateva G, Harris NI. Real-world data for use in the real world: the pain paradigm. Ispor Connections. 2013;19(2):9-11.
Harris JR, Patel MK, Juliao PS, Suchdev PS, Ruth LJ, Were V, Ochieng C, Faith SH, Kola S, Otieno R, Sadumah I, Obure A, Quick R. Addressing inequities in access to health products through the use of social marketing, community mobilization, and local entrepreneurs in rural Western Kenya. J Popul Res. 2012;2012:470598. doi: 10.1155/2012/470598
Wolowacz SE, Khan SB. The New National Institute of Health and Clinical Excellence (NICE) Single Technology Appraisal (STA) process: experience from the first completed appraisals. Ispor Connections. 2007;13(2):12-5.
Mansfield CA. A consistent method for calibrating contingent value survey data. South Econ J. 1998;64(3):665-81.